Lantheus Holdings (LNTH) Share-based Compensation (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly Share-based Compensation of $15.7 million for Q1 2026, down 33.74% year-over-year from $23.7 million in Q1 2025, and up 137.65% quarter-over-quarter from -$41.7 million in Q4 2025.
Lantheus Holdings (LNTH) Share-based Compensation (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Share-based Compensation for 13 consecutive years, with $15.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 33.74% year-over-year to $15.7 million; the TTM figure through Mar 2026 stood at $20.8 million (up 149.07% YoY), while the FY2025 annual figure was $26.3 million, up 41706.35% from the prior year.
- Share-based Compensation grew to $15.7 million in Q1 2026 per LNTH's latest filing, from -$41.7 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $29.3 million in Q4 2022 and bottomed at -$54.2 million in Q4 2024.
- Historically, Share-based Compensation has averaged $6.5 million across 5 years, with a median of $14.0 million in 2023.
- On a YoY basis, Share-based Compensation climbed as much as 525.56% in 2024 and fell as far as 255.63% in 2024.
- Lantheus Holdings' Share-based Compensation stood at $29.3 million in 2022, then sank by 152.05% to -$15.2 million in 2023, then tumbled by 255.63% to -$54.2 million in 2024, then advanced by 23.05% to -$41.7 million in 2025, then jumped by 137.65% to $15.7 million in 2026.
- Business Quant data shows LNTH's Share-based Compensation at $15.7 million in Q1 2026, -$41.7 million in Q4 2025, and $24.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Lantheus Holdings | 6.54 Bn | 5.94 Bn | 241.86 Mn | 20.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.01 Mn |
| Jun 30, 2026 | 20.01 Mn |
| Mar 31, 2026 | 15.70 Mn |
| Mar 31, 2026 | 15.70 Mn |
| Dec 31, 2025 | -41.68 Mn |
| Dec 31, 2025 | -41.68 Mn |
| Sep 30, 2025 | 24.50 Mn |
| Sep 30, 2025 | 24.50 Mn |
| Jun 30, 2025 | 22.32 Mn |
| Jun 30, 2025 | 22.32 Mn |
| Mar 31, 2025 | 23.69 Mn |
| Mar 31, 2025 | 23.69 Mn |
| Dec 31, 2024 | -54.17 Mn |
| Dec 31, 2024 | -54.17 Mn |
| Sep 30, 2024 | 20.37 Mn |
| Sep 30, 2024 | 20.37 Mn |
| Jun 30, 2024 | 18.48 Mn |
| Jun 30, 2024 | 18.48 Mn |
| Mar 31, 2024 | 19.42 Mn |
| Mar 31, 2024 | 19.42 Mn |